Healios will expand the possibilities for curing diseases to increase and further enrich quality of life through the development and supply of iPSC regenerative medicine products as part of the rapid progress of regenerative medicine taking place in the biotechnological revolution.
CEO: Hardy TS Kagimoto
CMO: Masanori Sawada
5 articles with Healios
Healios K.K., Japan's leading clinical-stage biotechnology company, has been creating Universal Donor Cells, which are next-generation iPS cells created with gene-editing technology to engineer a low risk of immune rejection regardless of HLA types.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 14, 2020.
Healios K.K. to Highlight Its Novel Approach in Regenerative Medicine at the Upcoming 38th Annual J.P. Morgan Healthcare Conference and Biotech Showcase in San Francisco, CA
Healios K.K. Japan's leading clinical stage biotechnology company harnessing the potential of stem cells for regenerative therapies announces that its Chairman and Chief Executive Officer, Hardy TS Kagimoto, MD, will provide a strategic overview and company update at the 38th Annual J.P. Morgan Healthcare Conference.
Healios Receives Notification of Orphan Designation for Acute Respiratory Distress Syndrome Clinical ProgramDesignation will expedite review for HLCM051 (MultiStem® Cell Therapy) for ARDS program in Japan
Athersys, Inc. announced that its collaborator in Japan, HEALIOS K.K. received notification this week from the Pharmaceutical Affairs and Food Sanitation Council that its acute respiratory distress syndrome clinical program using HLCM051, will receive the orphan regenerative medicine designation from the Ministry of Health, Labour and Welfare within the next few weeks.
HEALIOS Announces Enrollment of First Patient in Japan in TREASURE Study of MultiStem Treatment for Ischemic Stroke
Off-the-shelf stem cell therapy has potential to extend treatment window and enhance recovery for stroke patients.